Investment Rating - The report initiates coverage on the company with a "Buy" rating [6][20]. Core Insights - The company is expected to achieve revenues of 261, 301, and 348 billion yuan for the years 2025, 2026, and 2027, representing year-on-year growth of +13%, +15%, and +16% respectively. The net profit attributable to shareholders is projected to be 27.2, 32.3, and 37.3 billion yuan for the same years, with year-on-year growth of +17%, +19%, and +16% respectively, corresponding to current P/E ratios of 16.7, 14.0, and 12.1 [2][6][18]. Summary by Sections 1. Company Overview - The company is the world's largest battery box supplier, deeply rooted in the European market, and is expected to benefit significantly from the acceleration of electrification in the European automotive market [3][25]. - The company has established strategic partnerships in emerging fields such as robotics, liquid cooling, and low-altitude economy, aiming to create a second growth curve [4][25]. 2. Battery Box Business - The battery box business is projected to contribute significantly to revenue growth, with expected revenues of 75, 105, and 141 billion yuan from 2025 to 2027, reflecting year-on-year growth of +40% for 2025 and 2026, and +35% for 2027 [3][14]. - The European market's clear carbon emission targets and the resumption of electric vehicle subsidies are driving the growth of the battery box segment, with expected sales of 3.86 million new energy vehicles in Europe by 2025, a year-on-year increase of +31% [3][66]. 3. Emerging Business Areas - The company is expanding into robotics, liquid cooling, and low-altitude operations, which are expected to contribute to revenue and profit growth. Strategic collaborations with leading companies in these fields have been established [4][14]. - The robotics segment is anticipated to see significant developments, with a focus on smart exterior parts and flexible manufacturing solutions [4][25]. 4. Financial Projections - The company’s revenue is expected to grow from 20,523.67 million yuan in 2023 to 34,839.70 million yuan in 2027, with a compound annual growth rate (CAGR) of 15.71% [5][18]. - The net profit is projected to increase from 1,903.23 million yuan in 2023 to 3,731.72 million yuan in 2027, with a CAGR of 15.62% [5][18]. 5. Market Position and Strategy - The company has a clear and concentrated ownership structure, ensuring stable strategic decision-making and operational management [31][39]. - The company has diversified its customer base, collaborating with over 80 global automotive brands, including major players in the electric vehicle sector [39][40].

Investment Rating - The report assigns a "Buy" rating for Kuaishou (1024.HK) with a target price of HKD 86, indicating a potential upside of 42% from the current price of HKD 60.75 [7][18]. Core Insights - The report highlights the strong commercialization potential of Kuaishou's AI technology, Keling AI, which is expected to maintain its technological and commercial leadership. The AI's capabilities in enhancing advertising and e-commerce are emphasized, along with the resilience of its differentiated content ecosystem [1][16]. - By December 2025, Keling AI is projected to have over 60 million global users and generate more than 20 million USD in monthly revenue, translating to an annual recurring revenue (ARR) of 240 million USD [2]. - The report estimates that the potential market size for video generation models could reach between 17 billion USD and 38 billion USD by 2030, with a long-term potential of 90 billion USD [2][16]. Financial Forecast - Total revenue for Kuaishou is expected to reach 142.2 billion CNY in 2025 and 156.6 billion CNY in 2026, reflecting year-on-year growth of 12% and 10% respectively. Online marketing revenue is projected to grow by 12% and 11% in the same periods [3][12]. - Adjusted net profit is forecasted to be 20.4 billion CNY in 2025 and 22.4 billion CNY in 2026, with growth rates of 15% and 10% respectively [3][12]. - The report anticipates that the increase in operating expenses will primarily stem from R&D investments to support Keling AI's development [3]. Valuation - The report employs a Sum-of-the-Parts (SOTP) valuation method, assigning a target price of HKD 86. The main business is valued at 12 times the 2026 earnings, contributing HKD 70 to the target price, while Keling AI is valued at 30 times the 2026 sales, contributing HKD 16 [4][15]. - The overall valuation for Kuaishou is approximately 376 billion HKD, corresponding to a 2026 overall price-to-earnings ratio of 14.7 times [15][17]. Company Overview - Kuaishou has over 700 million monthly active users (MAU) and 420 million daily active users (DAU), with a DAU/MAU ratio of 57% and an average daily usage time of 134 minutes [21][30]. - The company has transitioned to a revenue model where online marketing services now account for 57% of total revenue, surpassing live streaming as the largest revenue contributor [36][41].

Investment Rating - The report initiates a "Buy" rating for Kuaishou (1024.HK) with a target price of HKD 86, indicating a potential upside of 42% from the current price of HKD 60.75 [1][7]. Core Insights - The report highlights the strong commercialization potential of Kuaishou's Keling AI, projecting that by December 2025, Keling AI will have over 60 million global users and generate monthly revenue exceeding USD 20 million, leading to an annual recurring revenue (ARR) of USD 240 million [2]. - The estimated market size for video generation models could reach USD 17 billion to USD 38 billion by 2030, with a long-term potential of USD 90 billion, indicating significant growth opportunities in the video generation sector [2][16]. - Kuaishou's total revenue is expected to reach CNY 142.2 billion in 2025 and CNY 156.6 billion in 2026, with a year-on-year growth of 12% and 10% respectively [3][5]. Financial Forecast - Total revenue projections for Kuaishou are CNY 1,422 billion for 2025 and CNY 1,566 billion for 2026, with online marketing revenue expected to grow by 12% and 11% respectively [3][12]. - Adjusted net profit is forecasted to be CNY 20.4 billion in 2025 and CNY 22.4 billion in 2026, reflecting a year-on-year increase of 15% and 10% [3][5]. - The report anticipates that Kuaishou's operating expenses will primarily increase due to R&D investments to support Keling AI's development [3][12]. Valuation - The report employs a Sum-of-the-Parts (SOTP) valuation method, assigning a target price of HKD 86, derived from a 12x P/E ratio for the core business and a 30x P/S ratio for Keling AI [4][15]. - The core business is valued at HKD 70 per share, while Keling AI contributes HKD 16 per share to the target price [4][15]. - The overall valuation for Kuaishou is approximately HKD 376 billion, corresponding to a 2026 P/E ratio of 14.7x [15][17]. Company Overview - Kuaishou has a monthly active user (MAU) base exceeding 730 million, with a daily active user (DAU) count of 420 million as of Q3 2025, indicating a stable user growth trajectory [21][27]. - The company has transitioned to a revenue model where online marketing services now account for 57% of total revenue, surpassing live streaming as the primary revenue source [36][41]. - Kuaishou's gross margin stands at 54% as of Q3 2025, benefiting from the high-margin online marketing services [41].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company's Q4 performance slightly exceeded expectations, with revenue surpassing forecasts by 5% and adjusted net profit exceeding expectations by 5% and 8% respectively [1][2] - The contribution of international business to total revenue is expected to increase to 40% by 2025, with management emphasizing investments in international operations and AI [1][3] - The report projects a 13% year-on-year revenue growth for 2026, while adjusted net profit is revised down by 5% to 202 billion RMB, with a profit margin of 28.6% [4] Financial Performance Summary - Q4 2025 net revenue reached 15.4 billion RMB, a 21% year-on-year increase, exceeding expectations [2] - Adjusted net profit for Q4 2025 was 3.5 billion RMB, surpassing forecasts by 5% and 8% [2] - The gross margin for Q4 2025 remained stable at 79%, with a 20% year-on-year increase in gross profit [2] - The company expects total revenue for Q1 2026 to grow by 15%, with accommodation and transportation bookings projected to increase by 16% and 10% respectively [4] Operational Highlights - In 2025, the core OTA business GMV was 1.1 trillion RMB, a decrease of 8% year-on-year, with accommodation and flight bookings contributing approximately 280 billion RMB and 550 billion RMB respectively [3] - International OTA platform bookings increased by about 60% year-on-year, with management highlighting a focus on inbound tourism and AI innovation [3] - The company plans to invest 2.9 billion RMB in user experience improvements and over 1 billion RMB in inbound tourism initiatives [3] Valuation and Forecast - The report maintains a target price of 541 HKD (9961.HK) / 69 USD (TCOM.US) based on a 16x P/E ratio for 2026 [4][6] - The company is projected to achieve a net profit margin of 28.6% in 2026, with long-term profit margins expected to remain above 30% [4]

Investment Rating - The report maintains a "Strong Buy" rating for Weitai Medical-B (02235.HK) [1] Core Views - The company recently announced a positive earnings forecast for 2025, projecting revenue of no less than 650 million yuan, representing a year-on-year growth of approximately 88.1%, and achieving a net profit of no less than 38 million yuan, reversing a loss of 63 million yuan in the same period last year [1] - Revenue growth is primarily driven by strong performance in core products, particularly Continuous Glucose Monitoring (CGM) systems, and significant expansion in overseas markets [6] - The company has successfully entered multiple countries with its LinX CGM system, leading to substantial international revenue growth [6] - The company is expected to continue high growth in overseas markets in 2026, with recent approvals in populous countries like India and Brazil [6] - The closed-loop artificial pancreas is anticipated to receive approval in 2026, which will enhance the company's diabetes management product portfolio [6] - The target market capitalization is set at 5.9 billion HKD, corresponding to a target price of 14.0 HKD per share, based on a 4x PS valuation for the main business [6] Financial Summary - Total revenue projections for 2025-2027 are 651 million, 882 million, and 1,161 million yuan, with year-on-year growth rates of 88.3%, 35.6%, and 31.6% respectively [6] - Net profit projections for the same period are 38 million, 93 million, and 152 million yuan, with year-on-year growth rates of 160.7%, 143.2%, and 63.5% respectively [6] - The company has a total market capitalization of 3.196 billion HKD and a circulating market value of 1.257 billion HKD [3]

Investment Rating - The report maintains a "Strong Buy" rating for Weitai Medical-B (02235.HK) [1] Core Views - The company recently announced a positive earnings forecast for 2025, projecting revenue of no less than 650 million yuan, representing a year-on-year growth of approximately 88.1%, and achieving a net profit of no less than 38 million yuan, reversing a loss of 63 million yuan in the same period last year [1] - Revenue growth is primarily driven by strong performance in core products, particularly Continuous Glucose Monitoring (CGM) systems, and significant expansion in overseas markets [6] - The company has successfully entered multiple countries with its LinX CGM system, leading to substantial international revenue growth [6] - The company is expected to continue high growth in overseas markets in 2026, with recent approvals in populous countries like India and Brazil [6] - The closed-loop artificial pancreas is anticipated to receive approval in 2026, which will enhance the company's diabetes management product portfolio [6] - The target market capitalization is set at 5.9 billion HKD, corresponding to a target price of 14.0 HKD per share, based on a 4x PS valuation for the main business [6] Financial Summary - For the fiscal years 2024A to 2027E, the projected total revenue is as follows: - 2024A: 346 million yuan - 2025E: 651 million yuan - 2026E: 882 million yuan - 2027E: 1,161 million yuan - Year-on-year growth rates for total revenue are projected at 36.5%, 88.3%, 35.6%, and 31.6% respectively [1][7] - The net profit forecast for the same period is: - 2024A: -63 million yuan - 2025E: 38 million yuan - 2026E: 93 million yuan - 2027E: 152 million yuan - Year-on-year growth rates for net profit are projected at 49.5%, 160.7%, 143.2%, and 63.5% respectively [1][7] - The company’s earnings per share (EPS) is expected to improve from -0.15 yuan in 2024A to 0.36 yuan in 2027E [1][7]

Investment Rating - The report maintains a "Buy" rating for Hong Kong Exchanges and Clearing Limited (00388.HK) [9] Core Views - The overall performance of Hong Kong Exchanges reached a historical high, with revenue and other income for 2025 amounting to HKD 291.61 billion, a year-on-year increase of 30.3%, and a net profit attributable to shareholders of HKD 177.54 billion, up 36.0% year-on-year [5][9] - The report anticipates that with a series of connectivity policies, market liquidity in Hong Kong will continue to rise, leading to increased market activity and valuation [9] Summary by Relevant Sections Financial Performance - In 2025, the company achieved revenue of HKD 291.61 billion, representing a 30.3% increase year-on-year, and a net profit of HKD 177.54 billion, which is a 36.0% increase year-on-year [5][9] - Revenue breakdown by fee type shows significant growth: trading and trading system usage fees increased by 43.73%, listing fees by 20.55%, and settlement and clearing fees by 49.29% [9] Market Activity - The trading activity in the cash, derivatives, and commodities markets saw substantial increases, with the average daily turnover of stock securities rising by 92.9% year-on-year [9] - The report highlights that the number of new listings and the amount raised in the Hong Kong market have also increased significantly, with 119 new companies listed in 2025, raising funds that grew by 236.1% year-on-year [9] Future Projections - The company is projected to achieve revenue and other income of HKD 326.14 billion, HKD 344.03 billion, and HKD 363.26 billion for the years 2026, 2027, and 2028 respectively, with net profits expected to be HKD 203.53 billion, HKD 214.24 billion, and HKD 225.93 billion [9][10] - Corresponding PE ratios are forecasted to be 25.88, 24.58, and 23.31 for the years 2026, 2027, and 2028 [9]

Investment Rating - The report maintains an "Accumulate" rating for Xiaomi Group (1810.HK) [1] Core Insights - The smartphone and IoT business are expected to face short-term pressure, with adjusted profits projected to decline year-on-year in Q4 2025 [2] - Xiaomi Group's revenue for Q4 2025 is anticipated to be CNY 116.4 billion, representing a 7% year-on-year growth, despite declines in smartphone and IoT revenues [5][6] - The electric vehicle segment is projected to see significant growth, with revenues expected to reach CNY 38 billion, a 133% increase year-on-year [7] Financial Projections - Revenue and profit forecasts for Xiaomi Group from 2025 to 2027 are as follows: - 2025: Revenue of CNY 455.6 billion, adjusted net profit of CNY 39.1 billion - 2026: Revenue of CNY 546.1 billion, adjusted net profit of CNY 42.7 billion - 2027: Revenue of CNY 643.1 billion, adjusted net profit of CNY 55 billion - Corresponding adjusted P/E ratios are projected to be 19.5x for 2025, 17.8x for 2026, and 13.9x for 2027 [7][10][11] Business Segment Analysis - **Smartphone Business**: Expected revenue of CNY 45.2 billion in Q4 2025, a 12% decline year-on-year, with a gross margin of approximately 8.3% [6] - **IoT and Consumer Products**: Anticipated revenue of CNY 23.3 billion in Q4 2025, a 25% decline year-on-year, with a gross margin of around 20% [6] - **Electric Vehicle Business**: Projected revenue of CNY 38 billion in Q4 2025, driven by an expected delivery of approximately 150,000 vehicles [7]

Investment Rating - The investment rating for Jiangnan Buyi (03306.HK) is "Outperform the Market" [5][20]. Core Views - The company achieved a revenue of 3.376 billion yuan in the first half of FY2026, representing a year-on-year growth of 7.0%, demonstrating resilience and competitiveness in a challenging retail environment [1]. - The gross margin improved by 1.4 percentage points to 66.5%, driven by changes in channel structure, pricing strategies, and discount management [1]. - Net profit increased by 11.9% to 676 million yuan, with a net profit margin rising from 19.1% to 20.0% [1]. - The company reported a healthy operating cash flow of 999.6 million yuan, up 21.1% year-on-year, supporting its high dividend payout [1]. Summary by Sections Financial Performance - Online revenue grew by 25.1% to 750 million yuan, accounting for 22.3% of total revenue, with a gross margin increase of 1.6 percentage points to 65.8% [2]. - Offline revenue saw a modest growth of 2.7%, with self-operated channels growing by 5.7% and distributor channels remaining flat [2]. - Comparable store sales declined by 2.2%, primarily due to the impact of a warm winter and the timing of the Spring Festival [2]. Brand Performance - The main brand, JNBY, accounted for 55.1% of total revenue, growing by 5.7% with a gross margin increase of 1.8 percentage points to 69.4% [2]. - The growth brand segment accounted for 37.9% of revenue, showing a slight decline of 0.2%, while the LESS brand performed well with a revenue increase of 16.3% and a gross margin improvement of 1.7 percentage points to 70.5% [2]. - Emerging brands represented 7.0% of revenue, growing by 22.4%, although their gross margin faced pressure, decreasing by 3.6 percentage points to 48.8% [2]. Earnings Forecast - The earnings forecast for FY2026-2028 has been adjusted upwards, with expected net profits of 960 million, 1.02 billion, and 1.07 billion yuan, reflecting year-on-year growth rates of 7.3%, 6.5%, and 4.7% respectively [3][21]. - The target price is set between 21.8 and 25.8 HKD, corresponding to a price-to-earnings ratio (PE) of 11-13x for FY2026 [3][20].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5]. Core Insights - The company reported total revenue of $5.3 billion for 2025, a year-on-year increase of 40%, and achieved a GAAP net profit of $287 million, marking a return to profitability [2]. - The sales of the core product, Zebutinib, continued to grow rapidly, with Q4 2025 sales reaching $1.15 billion, a 39% increase year-on-year [3]. - The company provided guidance for 2026, projecting total revenue between $6.2 billion and $6.4 billion, with GAAP operating expenses of $4.7 billion to $4.9 billion and a gross margin in the high 80% range [3]. Financial Performance - The company’s revenue is expected to grow from $5.34 billion in 2025 to $6.43 billion in 2026, reflecting a growth rate of 20.27% [10]. - The net profit forecast for 2026 is adjusted to $685 million, with a significant growth rate of 138.6% compared to 2025 [10]. - The diluted earnings per share (EPS) is projected to be $0.44 in 2026, up from $0.19 in 2025 [10]. Research and Development Pipeline - The company is advancing its R&D pipeline, with several key milestones expected in 2026, including interim analysis for Zebutinib in MCL and potential approvals for other products [4]. - The company anticipates data releases for various clinical trials in the first half of 2026, which could serve as catalysts for future growth [4].